Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0268
SPECIAL REPORT
|
Breakthrough blood test for early diagnosis, screening, patient monitoring and therapeutic response prediction.
|
Prof. Dr. Med Ernst Hanisch, MD.
|
Affiliation:Prof. Dr.med. Ernst Hanisch, Chefarzt und Ärztlicher Direktor, Klinik für Allgemein- Viszeral- und Endokrine Chirurgie, Asklepios Klinik Langen, Akademisches Lehrkrankenhaus der JWG-Universität Frankfurt, Röntgenstr 20, 63225 Langen .
Tel: 06103/912 61200; FAX: 06103/9121814,
Email: E.Hanisch@Asklepios.com |
Abstract
The recent rapid development of next-generation sequencing (NGS) of circulating cell-free DNA method has revolutionized cancer research. This breakthrough non-invasive technological system raises potential major clinical implications, including early cancer diagnosis, screening, decision-making for overcoming primary and acquired therapeutic resistance as well as patient monitoring. Challenges and clinical potential are discussed in this article.
(Citation: Gastric & Breast Cancer 2018; 13(1): 43-48)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 31 March 2018 |
|
